Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Globe Newswire26-02-2024, 14:05
OKX Launches 'Web3 DeFi Bonus Season' Campaign, Giving Users the Opportunity to Earn an Additional APR of Up to 14% 20-11-2023, 14:15